BTG2 and hepatocellular carcinoma: After HCC cells were pretreated with an ERK phosphorylation inhibitor (PD184352) for 24 h to block ERK activation, the increased BTG2 protein levels induced by PRMT5 inhibition were significantly suppressed (Fig. 5B).